R R

What Is a Narrow Therapeutic Index?

A narrow therapeutic index describes a medicine for which the difference between an effective exposure and a harmful or ineffective exposure is relatively small. Minor changes in dose, blood concentration, absorption, or metabolism can cause serious toxicity or treatment failure. These medicines require greater precision in prescribing, dispensing, and administration. The term is also expressed as narrow therapeutic window.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is a Narrow Therapeutic Index?

A narrow therapeutic index describes a medicine for which the difference between an effective exposure and a harmful or ineffective exposure is relatively small. Minor changes in dose, blood concentration, absorption, or metabolism can cause serious toxicity or treatment failure. These medicines require greater precision in prescribing, dispensing, and administration. The term is also expressed as narrow therapeutic window.

read more about narrow therapeutic index ...

Copy this HTML:

Copy HTML Copied!

Why Do Narrow-Therapeutic-Index Drugs Require Care?

Small changes in exposure can move a patient outside the desired therapeutic range. Kidney or liver impairment, dehydration, illness, diet, genetics, and drug interactions can alter concentrations. Differences in adherence, formulation, or administration timing can also become clinically significant. The consequences depend on the drug and can include seizures, abnormal heart rhythms, bleeding, organ rejection, or loss of disease control.

What Are Examples of Narrow-Therapeutic-Index Drugs?

Commonly cited examples include warfarin, lithium, digoxin, tacrolimus, cyclosporine, and phenytoin. The exact classification and regulatory list can differ by authority and context. Some drugs require direct concentration measurement, while others are followed with a biological response such as the international normalized ratio for warfarin. Product-specific prescribing information determines the appropriate target and monitoring plan.

How Are Narrow-Therapeutic-Index Drugs Monitored?

Monitoring can include blood drug concentrations, coagulation tests, organ-function tests, electrolytes, symptoms, or disease-specific outcomes. Samples must sometimes be collected at a defined time relative to the dose. Clinicians interpret results together with adherence, dose history, interacting medicines, and clinical condition. Dose adjustments are commonly small and followed by repeat testing.

What Are the Safety and Interaction Considerations?

Starting or stopping another medicine can substantially change the exposure of a narrow-therapeutic-index drug. Switching formulations or manufacturers can require additional attention for selected products, even when approved equivalence standards are met. Patients should take the medicine consistently and should not change the dose, schedule, diet, or supplements without guidance. New toxicity symptoms or loss of treatment effect requires prompt review.

Frequently Asked Questions About Narrow Therapeutic Index

Is therapeutic index the same as therapeutic range?

No. Therapeutic index is a comparative measure of effective and toxic doses, while therapeutic range commonly refers to a target blood-concentration interval used in clinical care.

Do all narrow-therapeutic-index drugs require blood-level testing?

No. Some are monitored with blood concentrations, while others use coagulation tests, organ function, symptoms, or another clinical response.

Can food affect a narrow-therapeutic-index drug?

Yes. Food can alter absorption, metabolism, or the medicine's biological effect. Warfarin and vitamin K intake are a familiar example in which consistency is important.

Are generic narrow-therapeutic-index medicines approved differently?

Regulators can apply tighter or additional bioequivalence considerations to selected narrow-therapeutic-index drugs. Approved generics must meet the applicable product-specific standards.

References

Setting and Implementing Standards for Narrow Therapeutic Index Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/cder-conversations/setting-and-implementing-standards-narrow-therapeutic-index-drugs. Date Accessed August 6, 2026.

FY2015 Regulatory Science Research Report: Narrow Therapeutic Index Drugs. U.S. Food and Drug Administration. https://www.fda.gov/industry/generic-drug-user-fee-amendments/fy2015-regulatory-science-research-report-narrow-therapeutic-index-drugs. Date Accessed August 6, 2026.

ED50. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK538269/. Date Accessed August 6, 2026.

Warfarin Sodium Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=36a919ce-7a21-40c0-9af5-2299bf2b1f97. Date Accessed August 6, 2026.

PROGRAF (Tacrolimus) Capsules: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b. Date Accessed August 6, 2026.